百奥泰(688177) - 2023 Q1 - 季度财报

Revenue and Profitability - Revenue for the first quarter of 2023 was RMB 154,927,728.15, representing a year-on-year increase of 108.74%[14] - Net profit attributable to shareholders of the listed company was RMB -142,584,813.68, with no applicable year-on-year comparison[14] - Total operating revenue for Q1 2023 was 154.93 million yuan, a significant increase from 74.22 million yuan in Q1 2022[54] - Revenue for Q1 2023 increased to 154,927,728.15 RMB, up from 74,220,560.73 RMB in Q1 2022, driven by increased sales of Geleri and Pubeixi, as well as new sales of Shireli[63][71] - Net loss for Q1 2023 was -142,584,813.68 RMB, compared to -110,363,404.74 RMB in Q1 2022, primarily due to increased R&D expenses[55][63] - Sales revenue from goods and services in Q1 2023 was 155,398,601.68 RMB, up from 132,161,441.42 RMB in Q1 2022[57][68] - Total comprehensive loss for Q1 2023 was -142,605,965.73 RMB, compared to -110,360,149.72 RMB in Q1 2022[56] - Net loss for the quarter was 143,294,729.60 RMB, compared to 110,355,571.09 RMB in the previous period[84] - Total comprehensive income loss was 143,294,729.60 RMB, compared to 110,355,571.09 RMB in the previous period[84] Shareholder Information - The largest shareholder, Guangzhou Qixi Group Co., Ltd., holds 159,690,670 unrestricted shares[9] - Therabio International Limited, a company wholly owned by LI SHENGFENG, holds 47,177,729 unrestricted shares[9] - Guangzhou Qiaoxing Investment Partnership holds 23,173,326 unrestricted shares[9] - Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership holds 21,499,471 unrestricted shares[9] - Guangzhou Zhongke Yuechuang No. 3 Venture Capital Partnership holds 21,333,332 unrestricted shares[9] - Guangzhou Xingyu Investment Partnership holds 21,320,002 unrestricted shares[9] Financial Position and Cash Flow - The company's monetary funds increased to 403,737,896.95 yuan as of March 31, 2023, compared to 165,938,818.90 yuan at the end of 2022[24] - Trade receivables rose to 125,758,587.34 yuan in Q1 2023, up from 89,753,379.06 yuan at the end of 2022[24] - Prepayments decreased to 49,616,974.60 yuan in Q1 2023 from 90,742,071.11 yuan at the end of 2022[24] - The company's cash flow from operating activities was -146,153,513.54 yuan in Q1 2023, compared to -56,794,194.40 yuan in the same period last year[32] - Cash flow from investing activities was 109,965,906.97 yuan in Q1 2023, a significant improvement from -162,230,429.04 yuan in the same period last year[32] - Cash flow from financing activities was 248,688,164.52 yuan in Q1 2023, compared to -30,913,695.25 yuan in the same period last year[32] - Operating cash flow was -146.15 million yuan, indicating a significant cash outflow[42] - Operating cash flow for Q1 2023 was -145,550,657.10 RMB, compared to -57,439,540.21 RMB in Q1 2022, reflecting higher cash outflows[68] - Investment cash flow for Q1 2023 was 110,022,326.97 RMB, a significant improvement from -162,113,314.04 RMB in Q1 2022, driven by higher returns on investments[68] - Monetary funds rose to 402,013,368.15 RMB, up 145.7% from 163,587,091.76 RMB[82] - Accounts receivable increased to 125,756,994.07 RMB, a 40.1% rise from 89,753,379.06 RMB[82] - Inventory grew to 194,091,534.90 RMB, up 19.9% from 161,899,105.30 RMB[82] Assets and Liabilities - The company's total assets increased to 2,333,289,046.26 yuan as of March 31, 2023, up from 2,181,047,560.11 yuan at the end of 2022[36] - Fixed assets decreased slightly to 525,504,178.82 yuan in Q1 2023 from 530,182,492.20 yuan at the end of 2022[36] - Construction in progress increased to 170,400,112.06 yuan in Q1 2023 from 155,832,688.66 yuan at the end of 2022[36] - The company's total liabilities increased to 582,317,299.21 yuan in Q1 2023 from 538,160,579.49 yuan at the end of 2022[36] - Total assets increased by 7.02% to 2.33 billion yuan compared to the previous year-end[42] - Shareholders' equity attributable to the parent company decreased by 8.87% to 1.46 billion yuan[42] - Contract liabilities increased to 331,975,545.60 RMB, up 8.8% from 305,080,691.59 RMB[73] - Total current liabilities rose to 582,653,895.81 RMB, an 8.2% increase from 538,503,100.22 RMB[73] - Long-term borrowings surged to 253,252,458.33 RMB, a significant jump from 3,002,458.33 RMB[73] - Total non-current liabilities increased to 285,358,116.58 RMB, up 739.7% from 33,978,620.55 RMB[73] - Total liabilities grew to 868,012,012.39 RMB, a 51.6% increase from 572,481,720.77 RMB[73] R&D and Operating Costs - Non-recurring gains and losses amounted to RMB 27,392,763.89, primarily driven by government subsidies of RMB 27,697,013.28[5][16] - Total R&D investment was 231.02 million yuan, accounting for 149.11% of revenue, a decrease of 42.15 percentage points[42] - Total operating costs for Q1 2023 were 323.39 million yuan, up from 198.03 million yuan in Q1 2022[54] - R&D expenses for Q1 2023 were 231.02 million yuan, compared to 141.96 million yuan in Q1 2022[54] - R&D expenses for Q1 2023 surged to 233,112,801.12 RMB, up from 143,317,997.75 RMB in Q1 2022, mainly due to increased clinical trial and technical service fees[63][71] - The company's R&D investment as a percentage of revenue decreased by 42.15 percentage points, as revenue growth outpaced R&D expense growth[71] Earnings and Share Performance - Basic and diluted earnings per share were both -0.34 yuan per share, reflecting a loss[42] - Weighted average return on equity was -9.28%, showing a decline in profitability[42] - Basic and diluted earnings per share for Q1 2023 were both -0.34 RMB, compared to -0.27 RMB in Q1 2022[56]